2022 Ljubljana, Slovenia

II-04 Khalil Ben Hassine
A physiologically based pharmacokinetic modelling and “virtual twin” simulation approach for the prediction of busulfan exposure in young children undergoing hematopoietic stem cell transplantation.
Wednesday 15:10-16:40
II-05 Andrzej Bienczak
Application of model informed drug development to pediatric program for ligelizumab in Chronic Spontaneous Urticaria
Wednesday 15:10-16:40
II-12 Suthunya Chupradit
Population Pharmacokinetic analysis of lopinavir in children with HIV in Africa receiving the pediatric lopinavir/ritonavir pellets formulation
Wednesday 15:10-16:40
II-19 Aline Engbers
Understanding patent ductus arteriosus closure in preterm infants by detangling the effects of patient characteristics, treatment timing and ibuprofen exposure
Wednesday 15:10-16:40
II-21 Klervi GOLHEN
Value of literature review to inform development and use of biologics in juvenile idiopathic arthritis
Wednesday 15:10-16:40
II-22 Verena Gotta
Characterizing associations of nocturnal glycemic control with QTc interval in children with type 1 diabetes – a model-based analysis
Wednesday 15:10-16:40
II-25 Paul Healy
In silico evaluation of the effect of CYP2D6 and OCT1 genotype variants on the pharmacokinetics and clinical safety of tramadol in infants, children and adolescents
Wednesday 15:10-16:40
II-28 Zoe Kane
Model based estimation of posaconazole tablet and suspension oral bioavailability using real world electronic health record (EHR) and therapeutic drug monitoring (TDM) data in children.
Wednesday 15:10-16:40
II-29 Wannee kantasiripitak
Model-informed precision dosing during infliximab induction therapy to improve long-term deep remission rates in paediatric patients with inflammatory bowel diseases
Wednesday 15:10-16:40
II-50 Franziska Schädeli Stark
A model-informed learn-confirm approach for balovaptan paediatric dose selection to achieve adult-equivalent drug exposure
Wednesday 15:10-16:40
II-58 Lufina Tsirizani Galileya
A pooled pharmacokinetic analysis of rifampicin, isoniazid, and pyrazinamide in paediatric patients with tuberculosis.
Wednesday 15:10-16:40
II-60 Anne van Rongen
Decision tables for the selection of allometric and other methods to scale adult drug clearance to children: making it as simple as possible but not simpler
Wednesday 15:10-16:40
II-61 Roeland Wasmann
A semi-mechanistic population pharmacokinetic model of tenofovir alafenamide fumarate and tenofovir in paediatric patients living with HIV
Wednesday 15:10-16:40
II-62 Yunjiao Wu
Maturation of formation clearance of paracetamol metabolites after intravenous paracetamol dosing in preterm neonates
Wednesday 15:10-16:40